Aristotle University Of Thessaloniki (AUTH)
Μελέτη βιολογικών ρόλων των SR πρωτεϊνικών κινασών σε Κ562 ερυθρολευχαιμικά κύτταρα: εμφάνιση αυτοαντισωμάτων απέναντι στην SRPK1 σε ασθενείς με νόσο Alzheimer
Abstract
dc:descriptionSPRK1 represents the most studied member of the serine/arginine family of kinases, which specifically phosphorylate serine residues within serine-arginine⁄arginine-serine domains. During the first part of this study, we investigated the possible impact of SRPK1 down-regulation, by applying RNAi technology, in K562 cells. Down-regulation of SRPK1 expression levels in K562 cells induces erythroid differentiation. A dominant cytoplasmic distribution of SRPK1 was observed in these cells, whereas a minor fraction of the kinase was found in the nucleus. Interestingly, a fraction of the cytoplasmic kinase, was found to be associated with polysomes.SRPK1 post-transcriptional down-regulation results in decreased phosphorylation of a certain number of proteins associated with the polysomal fraction. Following LC-MS/MS analysis, we identified a set of 28 proteins, participating in various aspects of mRNA maturation, transport and translation. TAF15 was one of the identified proteins. We present evidence that TAF15 is not phosphorylated by SRPK1. However, these two proteins were found to interact in vitro via SRPK1’s first catalytic domain and most importantly TAF15 was shown to negatively regulate SRPK1 activity. TAF15 localizes almost exclusively in the nucleus of K562 and HeLa cells. Taking into account the prevalent cytoplasmic localization of SRPK1, the two proteins do not seem to interact under normal cellular conditions. However, SRPK1 translocates to the nucleus, following genotoxic stress of HeLa cells, where it co-localizes with TAF15 in the periphery of particular subnuclear structures. This interaction is functional, as TAF15 could inhibit SRPK1-mediated splicing of a reporter gene, in an in vivo splicing assay. In the second part of this study, we investigated the potential implication of SRPK1 in the immunopathobiological mechanisms leading to Alzheimer’s disease (AD) development, by detecting specific autoantibodies against SRPK1 in the sera and cerebrospinal fluid of AD patients. In particular, a significant difference in anti-SRPK1 serum autoantibodies between Alzheimer’s disease patients and control individuals was observed (p=0.031). Furthermore, the epitopes mainly recognized by the antibodies in AD patients were mapped within the first catalytic domain of the kinase (p= 0.029). Elevated levels of SRPK1 autoantibodies were also detected in cerebrospinal fluid samples of the patients.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2013
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Daniilidou, Makrina
- Δανιηλίδου, Μακρίνα
Subjects
dc:subject × 9Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/34959